Skip to main content
Veterinary Medicines

GABBROVET 140 MG/ML SOLUTION FOR USE IN DRINKING WATER, MILK OR MILK REPLACER FOR PRE-RUMINANT CATTLE AND PIGS

Authorised
  • Paromomycin sulfate

Auðkenning lyfsins

Heiti lyfs:
GABBROVET 140 MG/ML SOLUTION FOR USE IN DRINKING WATER, MILK OR MILK REPLACER FOR PRE-RUMINANT CATTLE AND PIGS
Virkt efni:
Dýrategundir:
  • Nautgripir
  • Svín
Íkomuleið:
  • Til inntöku

Upplýsingar um lyfið

Virkt efni / Styrkur:
  • Aðeins í boði í English
    200.00
    milligram(s)
    /
    1.00
    millilitre(s)
Lyfjaform:
  • Lausn til notkunar í drykkjarvatn
Withdrawal period by route of administration:
  • Oral use
    • Nautgripir
      • Kjöt og innmatur
        20
        dagar
    • Svín
      • Kjöt og innmatur
        3
        dagar
ATC flokkun (dýralyf):
  • QA07AA06
Staða markaðsleyfis:
  • Gilt
Authorised in:
Þessar upplýsingar eru ekki tiltækar fyrir þessa vöru.
Áletrun:

Viðbótarupplýsingar

Entitlement type:
  • Markaðsleyfi
Markaðsleyfishafi:
  • Ceva Sante Animale
Marketing authorisation date:
Framleiðandi sem ber ábyrgð á lokasamþykkt:
  • Ceva Sante Animale
Ábyrgt yfirvald:
  • Le Ministere De La Sante Division De La Pharmacie Et Des Medicaments
Markaðsleyfisnúmer:
  • V 915/18/05/1699
Dagsetning leyfisbreytingar:
Umsjónarland (RMS):
  • Frakkland
Númer verkferlis:
  • FR/V/0317/001
Þátttökulönd (CMS):
  • Austurríki
  • Belgía
  • Búlgaría
  • Króatía
  • Kýpur
  • Tékkland
  • Danmörk
  • Eistland
  • Þýskaland
  • Grikkland
  • Ungverjaland
  • Ísland
  • Írland
  • Ítalía
  • Lettland
  • Litáen
  • Lúxemborg
  • Holland
  • Pólland
  • Portúgal
  • Rúmenía
  • Slóvakía
  • Slóvenía
  • Spánn
  • Bretland (Norður-Írland)
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."